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Acylation of tRNA.  Acylation reaction conditions as follows: 10-30 µg tRNA (~4-12 µM), 80 mM HEPES 
pH 7.5, 15-80 mM amino acid ethyl phosphate, 15-80 mM La(OTf)3 (1 equivalent to aaEP) in a final 
volume of 100 µL.  Addition of La3+ starts the reaction and generates insoluble complexes.  The reaction is 
stirred vigorously at room temperature for 30 minutes.  The reaction is quenched by addition of 50 µL of 
300 mM diethylene triamine pentaacetic acid (DTPA) and 1.25 M NH4OAc pH 7.5 (final concentrations 
100 mM DTPA and 417 mM NH4OAc).  Excess amino acid is extracted with 1 volume of 25:24:1 
phenol:chloroform:isoamyl alcohol pH 5.2.  The organic layer was then extracted with 0.5 volume of 
DTPA/NH4OAc quench solution.  The combined aqueous solutions were then washed with 1 volume of 
24:1 chloroform:isoamyl alcohol.  tRNA was then precipitated by addition of 3 volumes of ethanol and 
storage at -20 °C overnight.  tRNA was pelleted by centrifugation and dissolved in 1 mM NaOAc pH 4.5, 
followed by removal of co-precipitated DTPA-La using a CHROMA SPIN DEPC-water gel filtration 
column (Clontech, Mountain View, CA).  The resulting tRNA solution was used directly for MALDI-MS 
analysis or protein expression. 
 
Protein expression in Xenopus oocytes. Mouse muscle α1, β1, δ, and γ; and rat neuronal α4 and β2 
nAChR cDNA in the pAMV vector was linearized with the restriction enzyme Not I.  mRNA was prepared 
by in vitro transcription using the mMessage Machine T7 kit (Ambion, Austin, TX).  Unnatural mutations 
were introduced by the standard Stratagene QuickChange protocol using a TAG or TGA mutation at the 
site of interest.  The α4 subunit contained a known mutation in M2 transmembrane helix (L9’A).  Stage V-
VI Xenopus laevis oocytes were injected with mRNA in a 10:2:1:1 for α12β12δγ or 1:20 for α42β23.  
Stoichiometry of α4β2 confirmed by monitoring I-V relationships of acetylcholine-induced currents as 
described previously.1  Each cell was injected with 50 nL of a mixture of mRNA (10-19 ng, typically ~13 
ng): tRNA (3-42 ng, typically ~27 ng). Uncharged full length tRNA was injected as a negative control. 
 
Electrophysiology.  Electrophysiology experiments were performed 24-48 hours after injection using the 
OpusXpress 6000A instrument (Axon Instruments, Union City, CA) in two-electrode voltage clamp mode 
at a holding potential of  -60 mV.  The running buffer was Ca2+-free ND96 solution (96 mM NaCl, 2 mM 
KCl, 1 mM MgCl2 and 5 mM HEPES, pH 7.5).  Oocytes were superfused with running buffer at 1 mL/min 
for 30s before application of acetylcholine for 15 s followed by a 116 s wash with the running buffer.  Data 
were sampled at 125 Hz and filtered at 50 Hz.  Acetylcholine chloride was purchased from Sigma-
Aldrich/RBI (St. Louis, MO).  Does-response data were obtained for ≥ 10 acetylcholine concentrations on 
≥ 15 cells.  All EC50 and Hill coefficient values were obtained by fitting does-response relations to the Hill 
equation (Inorm = 1 / [ 1 + (EC50/[ACh])n]) and are reported as means ± standard error of the fit.  A detailed 
error analysis of nonsense suppression experiments reveals data are reproducible to ±50% in EC50.2 
 
Synthesis 
Tetraethylammonium NVOC-leucine ethyl phosphate (1). A round bottom flask was charged with α-
NVOC-leucine (170 mg, 0.46 mmol) and N,N’-dicyclohexylcarbodiimide (94 mg, 0.46 mmol) in 10 mL of 
dry CH2Cl2.  Reaction allowed to stir for 10 minutes at room temperature.  A separately prepared solution 
of bis(tetraethylammonium) ethyl phosphate (175 mg, 0.46 mmol) in 10 mL dry CH2Cl2 was added via 
syringe.  Reaction allowed to stir for 4 hours at room temperature.  The reaction mixture was concentrated 
and resuspended in 5 mL of CH2Cl2.  Upon filtration, the organic solution was extracted three times with 5 
mL of water.  Saturated NaCl solution was added dropwise to aid in emulsion breaking.  The combined 
aqueous extracts were washed with 5 mL CHCl3 followed by lyophilization.  The resulting solid was 
extracted with CH2Cl2 and filtered.  Concentration of the CH2Cl2 solution gave a yellow foam 182 mg (66 
%).  Analytical sample obtained by reverse phase HPLC.  1H NMR (300 MHz, DMSO-d6) δ 7.76 (d, J = 
8.9 Hz, 1H), 7.68 (s, 1H), 7.17 (s, 1H), 5.34 (s, 2H), 4.03 – 3.91 (m, 1H), 3.90 (s, 3H), 3.84 (s, 3H), 3.70 
(dt, J = 14.3, 7.2 Hz, 2H), 3.17 (q, J = 7.3 Hz, 8H), 1.72 – 1.58 (m, 1H), 1.54 – 1.45 (m, 2H), 1.18 – 1.08 
(m, 12H), 1.03 (t, J = 7.1 Hz, 3H), 0.85 (dd, J = 12.9, 6.5 Hz, 6H).  13C NMR (126 MHz, CDCl3) δ 169.69, 
169.62, 155.57, 154.01, 147.91, 139.09, 128.76, 109.53, 107.99, 63.35, 61.81, 61.76, 56.80, 56.43, 53.62, 
53.58, 52.59, 41.35, 24.82, 23.08, 21.61, 16.64, 16.58, 7.78.  HRMS ES (–) m/z for C18H26N2O11P, found 
477.1259, calculated 477.1274. 
 
Tetraethylammonium N-NVOC-tyrosine ethyl phosphate (2).  A round bottom flask was charged with α-
NVOC-tyrosine (150 mg, 0.36 mmol) and N,N’-dicyclohexylcarbodiimide (147 mg, 0.71 mmol) in 1.5 mL 
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of dry THF and 1 mL of dry CH2Cl2.  Reaction allowed to stir for 4 minutes at room temperature.  A 
separately prepared solution of bis(tetraethylammonium) ethyl phosphate (91 mg, 0.24 mmol) in 4 mL dry 
CH2Cl2 was added via syringe.  Reaction allowed to stir for 19 hours at room temperature.  The reaction 
mixture was filtered, and extracted three times with 5 mL of water.  Saturated NaCl solution was added 
dropwise to aid in emulsion breaking.  The combined aqueous extracts were lyophilized.  The resulting 
solid was extracted with acetonitrile and filtered.  Concentration of the acetonitrile solution gave a yellow 
oil 92 mg (63 %).  Analytical sample obtained by reverse phase HPLC.  1H NMR (300 MHz, CD3CN) δ 
8.93 (br, 1H), 7.69 (s, 1H), 7.07 (d, J = 8.6 Hz, 3H), 6.78 (d, J = 8.5 Hz, 2H), 6.13 (d, J = 8.5 Hz, 1H), 5.39 
(s, 2H), 4.44 – 4.32 (m, 1H), 4.05 – 3.79 (m, J = 12.5, 5.1 Hz, 8H), 3.18 (q, J = 7.3 Hz, 8H), 3.14 – 3.05 
(m, 1H), 2.99 – 2.84 (m, 1H), 1.28 – 1.15 (m, 15H).  13C NMR (126 MHz, CD3CN) δ 168.88, 168.80, 
157.53, 155.99, 154.27, 147.96, 139.02, 130.28, 128.93, 127.23, 117.50, 115.60, 109.63, 108.09, 62.96, 
61.45, 61.40, 57.13, 56.62, 56.00, 52.24, 52.22, 52.19, 35.89, 16.18, 16.12, 6.93.  31P NMR (121 MHz, 
CD3CN) δ -8.52.  HRMS ES (–) m/z for C21H24N2O12P, found 527.1062, calculated 527.1067. 
 
Tetraethylammonium NVOC-tryptophan ethyl phosphate (3).  A round bottom flask was charged with α-
NVOC-tryptophan (107 mg, 0.24 mmol) and N,N’-dicyclohexylcarbodiimide (50 mg, 0.24 mmol) in 6 mL 
of dry THF.  Reaction allowed to stir for 10 minutes.  A separately prepared solution of 
bis(tetraethylammonium) ethyl phosphate (93 mg, 0.25 mmol) in 5 mL CH2Cl2 was then added via syringe.  
Reaction allowed to stir overnight at room temperature.  The reaction mixture was concentrated on a rotary 
evaporator and resuspended in 2.5 mL of CH2Cl2.  Filtration of the suspension gave an organic solution that 
was extracted three times with 2 mL of water. Combined aqueous extracts were washed with 2 mL of 
CHCl3 followed by lyophilization to give a yellow foam, 87.9 mg (55%).  Analytical sample obtained by 
reverse phase HPLC.  1H NMR (300 MHz, CDCl3) δ 11.41 (s, 1H), 7.67 (s, 1H), 7.62 – 7.42 (m, 3H), 7.12 
– 6.88 (m, 3H), 5.58 (d, J = 8.2 Hz, 1H), 5.47 (s, 2H), 4.80 – 4.60 (m, 1H), 4.18 – 4.01 (m, 2H), 3.96 (s, 
3H), 3.81 (s, 3H), 3.42 (d, J = 4.6 Hz, 2H), 2.93 (q, J = 7.3 Hz, 8H), 1.28 (t, J = 7.0 Hz, 3H), 1.01 (t, J = 7.1 
Hz, 12H).  13C NMR (75 MHz, CDCl3) δ 168.76, 168.63, 155.30, 153.81, 148.02, 139.33, 136.58, 128.41, 
128.36, 125.17, 120.96, 118.74, 117.72, 112.43, 110.09, 108.07, 107.85, 77.45, 77.02, 76.60, 63.40, 62.13, 
62.04, 56.60, 56.39, 52.25, 27.15, 16.68, 16.58, 7.25.  31P NMR (121 MHz, CDCl3) δ -7.76.  HRMS ES (–) 
m/z for C23H25N3O11P, found 550.1229, calculated 550.1227. 
 
Tetraethylammonium NVOC-5-fluorotryptophan ethyl phosphate (4).  A round bottom flask was charged 
with α-NVOC-5-fluorotryptophan (82 mg, 0.18 mmol) and N,N’-dicyclohexylcarbodiimide (42 mg, 0.20 
mmol) in 5 mL of dry THF.  Reaction allowed to stir for 10 minutes at room temperature.  A separately 
prepared solution of bis(tetraethylammonium) ethyl phosphate (72 mg, 0.19 mmol) in 5 mL dry CH2Cl2 
was added via syringe.  Reaction allowed to stir for 24 hours at room temperature.  The reaction mixture 
was concentrated and resuspended in 3 mL of CH2Cl2.  Upon filtration, the organic solution was extracted 
three times with 4 mL of water.  Saturated NaCl solution was added dropwise to aid in emulsion breaking.  
The combined aqueous extracts were lyophilized.  The resulting solid was extracted with CH2Cl2 and 
filtered.  Concentration of the CH2Cl2 solution gave a yellow foam 55 mg (44 %).  Analytical sample 
obtained by reverse phase HPLC.  1H NMR (400 MHz, CDCl3) δ 11.71 (s, 1H), 7.66 (s, 1H), 7.58 (d, J = 
2.1 Hz, 1H), 7.53 (dd, J = 8.7, 4.6 Hz, 1H), 7.09 (dd, J = 9.9, 2.3 Hz, 1H), 6.95 (s, 1H), 6.79 (td, J = 9.1, 
2.4 Hz, 1H), 5.59 (d, J = 8.2 Hz, 1H), 5.45 (d, J = 4.0 Hz, 2H), 4.70 – 4.62 (m, 1H), 4.14 – 4.04 (m, 2H), 
3.93 (s, 3H), 3.86 (s, 3H), 3.35 (ddd, J = 20.0, 14.9, 4.6 Hz, 2H), 2.98 (q, J = 7.3 Hz, 8H), 1.28 (t, J = 7.1 
Hz, 3H), 1.03 (t, J = 7.2 Hz, 12H).  13C NMR (126 MHz, CDCl3) δ 168.75, 168.68, 158.52, 156.67, 155.32, 
153.79, 148.02, 139.42, 133.12, 128.51, 128.44, 128.12, 127.17, 113.18, 113.11, 110.08, 109.25, 109.04, 
108.02, 107.84, 107.81, 102.35, 102.16, 63.52, 62.19, 62.14, 56.53, 56.37, 52.23, 27.08, 16.62, 16.56, 7.23.  
31P NMR (162 MHz, CDCl3) δ -7.83.  HRMS ES (–) m/z for C23H24N3O11FP, found 568.1110, calculated 
568.1133. 
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Supplemental Figure 1 MALDI mass spectra of THG73 tRNA after (below) exposure to La3+ mediated 
acylation conditions using tyrosine derivative 2 (top), tryptophan derivative 3 (middle), and fluro-
tryptophan derivative 4 (bottom).  Observed masses shown, theoretical masses in parentheses.  Based on 
calibration data, we estimate the yields at 15%, 10%, and 5% for 2, 3, and 4, respectively. 
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